Submitted by Guilherme Lemeszenski (guilherme@nead.unesp.br) on 2013-08-22T18:54:09Z No. of bitstreams: 1 S0101-60832010000600001.pdf: 260210 bytes, checksum: 2cedf1aa397e6e6bb51947c64786d8fe (MD5); Made available in DSpace on 2013-08-22T18:54:09Z (GMT). No. of bitstreams: 1 S0101-60832010000600001.pdf: 260210 bytes, checksum: 2cedf1aa397e6e6bb51947c64786d8fe (MD5) Previous issue date: 2010-01-01; Made availabl...
Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-27T11:28:10Z No. of bitstreams: 0Bitstream added on 2014-05-27T14:37:13Z : No. of bitstreams: 1 2-s2.0-84872131878.pdf: 264619 bytes, checksum: f1b166deaa25d9ab41c2fc74bbd08163 (MD5); Made available in DSpace on 2014-05-27T11:28:10Z (GMT). No. of bitstreams: 0 Previous issue date: 2013-01-16; Background: Several studies seek bi...
BACKGROUND: The objective of this study is to evaluate the efficacy of milnacipran in outpatients experiencing severe MDD non-respondent to adequate time and dosing of SSRI therapy. METHODS: A 12 week multi-centric study open study was designed to evaluate the efficacy of milnacipran after a SRRI trial failure. Complete remission (HAMD-17 < 8) was the principal outcome. Secondary outcomes were response (HAM >...